Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tamibarotene + arsenic trioxide
- Development stage
- Discontinued
- Lead developer
- LadRx
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Tamibarotene + arsenic trioxide is a combination therapy investigated for the treatment of relapsed or refractory acute promyelocytic leukemia (APL). Tamibarotene (Am80) is a synthetic retinoid and a selective agonist of the retinoic acid receptors alpha (RARα) and beta (RARβ), designed to induce terminal differentiation of leukemic cells and overcome resistance to all-trans retinoic acid (ATRA). Arsenic trioxide (ATO) is an antineoplastic agent that induces apoptosis and promotes the degradation of the PML-RARα fusion protein. This combination was evaluated in a Phase I clinical trial led by Northwestern University's Robert H. Lurie Comprehensive Cancer Center, with tamibarotene provided by CytRx Corporation, to determine the safety and efficacy of the regimen in patients who had relapsed after standard frontline therapy.
- Brand names
- Amnoid
- Other names
- Tamibarotene and Arsenic Trioxide
02
Targets
PML (Promyelocytic leukemia protein)PML-RARA (PML-retinoic acid receptor alpha fusion protein)RARA (Retinoic acid receptor alpha)Retinoic acid receptor alpha – corepressor complexRARB (Retinoic acid receptor beta)RXRA (Retinoid X receptor alpha)TRAC (T cell receptor alpha variable 17)
Beyond the preview
Go deeper on tamibarotene + arsenic trioxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tamibarotene + arsenic trioxide.